How Novartis’s Cosentyx Is Positioned after 3Q17


Nov. 14 2017, Updated 3:55 p.m. ET

Cosentyx revenue trends

In 3Q17, Novartis’s (NVS) Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ (quarter-over-quarter).

Article continues below advertisement

Future 5 trial

In November 2017, Novartis presented the results from its Future 5 trial, wherein Cosentyx demonstrated a reduction in signs and symptoms of psoriatic arthritis (or PsA) and substantial inhibition in the progression of joint structural damage in individuals with PsA compared with placebo therapy.

In the Future 5 trial, 996 participants were randomized to receive Cosentyx 300 mg (milligrams) with a loading dose (or LD), Cosentyx 150 mg with LD, and Cosentyx 150 mg without LD. Patients receiving Cosentyx demonstrated substantial progress in the signs and symptoms of PsA, according to the American College of Rheumatology (or ACR), with response criteria of 20% improvement (ACR20) at 16 weeks.

By comparison, Eli Lilly’s (LLY) Taltz, Amgen’s (AMGN) Enbrel, and Johnson & Johnson’s (JNJ) Stelara reported revenues of ~$151.3 million, ~$1.4 billion, and ~$1.1 billion, respectively, in 3Q17. Notably, the Vanguard FTSE All-World ex-US ETF (VEU) invests ~0.67% of its total portfolio holdings in Novartis.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.